BR112016013182A2 - classificação de câncer de próstata - Google Patents
classificação de câncer de próstataInfo
- Publication number
- BR112016013182A2 BR112016013182A2 BR112016013182A BR112016013182A BR112016013182A2 BR 112016013182 A2 BR112016013182 A2 BR 112016013182A2 BR 112016013182 A BR112016013182 A BR 112016013182A BR 112016013182 A BR112016013182 A BR 112016013182A BR 112016013182 A2 BR112016013182 A2 BR 112016013182A2
- Authority
- BR
- Brazil
- Prior art keywords
- prostate cancer
- methods
- individual
- rhb2
- pdrg1
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 5
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 abstract 1
- 101100317454 Caenorhabditis elegans xbp-1 gene Proteins 0.000 abstract 1
- 101150023376 Cebpd gene Proteins 0.000 abstract 1
- 101150029544 Crem gene Proteins 0.000 abstract 1
- 101100165098 Danio rerio b3gnt5a gene Proteins 0.000 abstract 1
- 101100403067 Danio rerio mtus1a gene Proteins 0.000 abstract 1
- 101100408262 Danio rerio pi15a gene Proteins 0.000 abstract 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 abstract 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 abstract 1
- 101100346152 Drosophila melanogaster modSP gene Proteins 0.000 abstract 1
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 101150026829 JUNB gene Proteins 0.000 abstract 1
- 101150013552 LDLR gene Proteins 0.000 abstract 1
- 108091007767 MALAT1 Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 101100178117 Mus musculus Hjurp gene Proteins 0.000 abstract 1
- 101100230601 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HBT1 gene Proteins 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000004590 computer program Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 abstract 1
- 101710098598 mRNA decay activator protein ZFP36 Proteins 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 101150023701 nfil3 gene Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 108010082379 somatostatin receptor type 1 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322034.8A GB201322034D0 (en) | 2013-12-12 | 2013-12-12 | Prostate cancer classification |
| PCT/GB2014/053694 WO2015087088A2 (en) | 2013-12-12 | 2014-12-12 | Prostate cancer classification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016013182A2 true BR112016013182A2 (pt) | 2017-09-26 |
Family
ID=50030858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013182A BR112016013182A2 (pt) | 2013-12-12 | 2014-12-12 | classificação de câncer de próstata |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10196697B2 (enExample) |
| EP (1) | EP3080293B1 (enExample) |
| JP (1) | JP2017507320A (enExample) |
| KR (1) | KR20160098351A (enExample) |
| CN (1) | CN105940117A (enExample) |
| AU (1) | AU2014363173A1 (enExample) |
| BR (1) | BR112016013182A2 (enExample) |
| CA (1) | CA2932553A1 (enExample) |
| GB (1) | GB201322034D0 (enExample) |
| IL (1) | IL246067A0 (enExample) |
| MX (1) | MX2016007333A (enExample) |
| SG (1) | SG11201604508PA (enExample) |
| WO (1) | WO2015087088A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11035005B2 (en) | 2012-08-16 | 2021-06-15 | Decipher Biosciences, Inc. | Cancer diagnostics using biomarkers |
| EP3359692A4 (en) * | 2015-10-05 | 2019-05-01 | Cedars-Sinai Medical Center | METHOD FOR CLASSIFYING AND TREATING CANCER |
| WO2017112860A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers |
| EP3405583B1 (en) * | 2016-01-20 | 2024-04-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for screening and identifying clinically aggressive prostate cancer |
| US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| EP3593140A4 (en) * | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| EP4428157A3 (en) | 2017-08-04 | 2024-12-11 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| WO2019195658A1 (en) * | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| CN113711316A (zh) * | 2019-01-30 | 2021-11-26 | 詹森药业有限公司 | 基于分子亚型治疗前列腺癌的方法 |
| GB201917428D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Newcastle | Prostate cancer diagnostic |
| CN111518908B (zh) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | 尿液前列腺癌标志物组合及其在制备精准诊断试剂中的用途 |
| EP3960876A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to radiotherapy based on pde4d7 correlated genes |
| EP3960878A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Selection of a dose for radiotherapy of a prostate cancer subject |
| EP3960877A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject |
| JP7477872B2 (ja) * | 2020-09-30 | 2024-05-07 | 国立大学法人大阪大学 | 癌に関連する新規バイオマーカー |
| CN113234820A (zh) * | 2021-04-29 | 2021-08-10 | 北京艾克伦医疗科技有限公司 | 鉴定前列腺癌状态的方法和试剂盒 |
| US20250109442A1 (en) * | 2022-01-13 | 2025-04-03 | Oslo Universitetssykehus Hf | Prostate cancer markers and uses thereof |
| EP4253567A1 (en) | 2022-03-31 | 2023-10-04 | OncoAssure Limited | A method of predicting risk of an aggressive or recurrent cancer |
| WO2023220314A1 (en) * | 2022-05-12 | 2023-11-16 | Veracyte SD, Inc. | Prognosis and treatment of molecular subtypes of prostate cancer |
| CN116891523B (zh) * | 2023-05-24 | 2024-05-17 | 深圳晶蛋生物医药科技有限公司 | 一种trpm3截短体、包含其的细胞系及其用途 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
| KR0148265B1 (ko) | 1988-12-16 | 1998-10-15 | 에프.지이.엠 헤르만스 | 자가-지속 서열 복제 시스템 |
| US5437975A (en) | 1991-02-25 | 1995-08-01 | California Institute Of Biological Research | Consensus sequence primed polymerase chain reaction method for fingerprinting genomes |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US7220557B2 (en) | 1997-04-24 | 2007-05-22 | Human Genome Sciences, Inc. | METH1 polynucleotides |
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| WO2002031209A2 (en) | 2000-10-13 | 2002-04-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Genes related to development of refractory prostate cancer |
| IL155952A0 (en) | 2000-11-28 | 2003-12-23 | Wyeth Corp | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US20030108963A1 (en) | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| US20050032065A1 (en) | 2002-06-24 | 2005-02-10 | Afar Daniel E. H. | Methods of prognosis of prostate cancer |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| JP2007525220A (ja) * | 2004-02-27 | 2007-09-06 | オンコセラピー・サイエンス株式会社 | Ｐｉｎ−ｐｒｃ移行遺伝子 |
| WO2006091776A2 (en) * | 2005-02-25 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| US8349555B2 (en) | 2005-03-16 | 2013-01-08 | Gennadi V. Glinsky | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
| WO2006113529A2 (en) | 2005-04-15 | 2006-10-26 | Becton, Dickinson And Company | Diagnosis of sepsis |
| EP1717320A1 (en) | 2005-04-26 | 2006-11-02 | TopoTarget Germany AG | Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy |
| ATE486964T1 (de) | 2005-09-14 | 2010-11-15 | Ca Nat Research Council | Molekulares verfahren zur diagnose von prostatakrebs |
| US20070059753A1 (en) | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| EP1951911A2 (en) | 2005-11-08 | 2008-08-06 | Euclid Diagnostics LLC | Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| US20110045464A1 (en) | 2007-01-10 | 2011-02-24 | Henry Ford Health System | Methods and compositions for identification of prostate cancer markers |
| WO2008121132A2 (en) | 2007-03-30 | 2008-10-09 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| US8709731B2 (en) | 2007-08-24 | 2014-04-29 | Oncotherapy Science, Inc. | DKK1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2009151503A2 (en) | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| EP2268838A1 (en) | 2008-04-11 | 2011-01-05 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US20090298082A1 (en) | 2008-05-30 | 2009-12-03 | Klee George G | Biomarker panels for predicting prostate cancer outcomes |
| EP2315858A2 (en) | 2008-07-08 | 2011-05-04 | Source Precision Medicine, Inc. | Gene expression profiling for predicting the survivability of prostate cancer subjects |
| KR20110052627A (ko) | 2008-07-16 | 2011-05-18 | 다나-파버 캔서 인스티튜트 인크. | 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법 |
| US20100055705A1 (en) | 2008-08-29 | 2010-03-04 | Wilson Gerald M | Compositions and methods for diagnosing and treating cancer |
| EP2358912B1 (en) | 2008-10-30 | 2016-10-12 | Caris Life Sciences Switzerland Holdings GmbH | Methods for assessing rna patterns |
| EP2370813A4 (en) | 2008-12-04 | 2012-05-23 | Univ California | MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| RU2651474C2 (ru) | 2009-05-12 | 2018-04-19 | Конинклейке Филипс Электроникс Н.В. | Фосфодиэстераза 4d7 как маркер рака предстательной железы |
| CN102439176B (zh) | 2009-05-12 | 2018-11-23 | 皇家飞利浦电子股份有限公司 | 用作恶性的、激素-敏感的前列腺癌的标志物的磷酸二酯酶4d7 |
| EP3296743A1 (en) | 2009-06-04 | 2018-03-21 | Metanomics Health GmbH | Methods for diagnosing prostate carcinomas |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| EP2309273B1 (en) | 2009-09-16 | 2016-05-18 | ZEILLINGER, Robert | Novel tumor marker determination |
| AU2010326066A1 (en) | 2009-12-01 | 2012-06-21 | Compendia Bioscience, Inc. | Classification of cancers |
| WO2011094233A1 (en) | 2010-01-26 | 2011-08-04 | The Johns Hopkins University | Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens |
| US20130058925A1 (en) | 2010-02-26 | 2013-03-07 | Board Of Regents, The University Of Texas System | Epithelial biomarkers for cancer prognosis |
| CN105601727B (zh) | 2010-03-11 | 2020-01-10 | 肿瘤疗法科学股份有限公司 | Hjurp肽及包含它们的疫苗 |
| WO2011153287A2 (en) | 2010-06-01 | 2011-12-08 | Indiana University Research And Technology Corporation | Materials and methods for diagnosing and predicting the course of prostate cancer |
| EP2591126B1 (en) | 2010-07-07 | 2020-12-30 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| EP2598890A4 (en) | 2010-07-26 | 2013-12-25 | Univ Johns Hopkins | MIG6 AND THERAPEUTIC EFFECTIVENESS |
| JP2013532482A (ja) | 2010-07-27 | 2013-08-19 | ジェノミック ヘルス， インコーポレイテッド | 遺伝子発現を用いた前立腺癌の予後を定量化する方法 |
| EP2611941A4 (en) | 2010-08-30 | 2014-01-22 | Myriad Genetics Inc | GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS |
| JP6181638B2 (ja) | 2011-04-28 | 2017-08-16 | ニューヨーク・ユニバーシティ | 前立腺癌における転移のゲノム・シグネチャー |
| AU2012275500A1 (en) | 2011-06-27 | 2014-01-16 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with prostate cancer progression and methods of use thereof |
| US20130079241A1 (en) * | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| GB201206209D0 (en) | 2012-04-06 | 2012-05-23 | Univ Leuven Kath | Marker gene based diagnosis, staging and prognosis of prostate caner |
| ES2673960T3 (es) | 2011-12-22 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1) |
| EP2809812A4 (en) | 2012-01-31 | 2016-01-27 | Genomic Health Inc | GENE EXPRESSION PROFILE ALGORITHM AND PROSTATE CANCER PROGNOSTIC DETERMINATION TEST |
| TW201343920A (zh) | 2012-03-29 | 2013-11-01 | Nat Health Research Institutes | 預測前列腺癌預後之分子標記、方法與套組 |
| BR102012007246A2 (pt) | 2012-03-30 | 2016-02-10 | Fundação Antonio Prudente | métodos para prognóstico e classificação de resultados de um evento |
| US20130288967A1 (en) | 2012-04-25 | 2013-10-31 | Euclid Diagnostics Llc | Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8 |
| CN103146688B (zh) | 2012-09-12 | 2015-05-13 | 上海长海医院 | 长链非编码rna作为疾病诊断血液分子标志物的应用 |
-
2013
- 2013-12-12 GB GBGB1322034.8A patent/GB201322034D0/en not_active Ceased
-
2014
- 2014-12-12 EP EP14814697.0A patent/EP3080293B1/en active Active
- 2014-12-12 KR KR1020167018629A patent/KR20160098351A/ko not_active Withdrawn
- 2014-12-12 US US15/103,770 patent/US10196697B2/en not_active Expired - Fee Related
- 2014-12-12 MX MX2016007333A patent/MX2016007333A/es unknown
- 2014-12-12 JP JP2016538689A patent/JP2017507320A/ja active Pending
- 2014-12-12 CA CA2932553A patent/CA2932553A1/en not_active Abandoned
- 2014-12-12 CN CN201480074318.2A patent/CN105940117A/zh active Pending
- 2014-12-12 AU AU2014363173A patent/AU2014363173A1/en not_active Abandoned
- 2014-12-12 BR BR112016013182A patent/BR112016013182A2/pt not_active Application Discontinuation
- 2014-12-12 SG SG11201604508PA patent/SG11201604508PA/en unknown
- 2014-12-12 WO PCT/GB2014/053694 patent/WO2015087088A2/en not_active Ceased
-
2016
- 2016-06-06 IL IL246067A patent/IL246067A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016007333A (es) | 2016-10-13 |
| EP3080293B1 (en) | 2019-03-13 |
| US10196697B2 (en) | 2019-02-05 |
| SG11201604508PA (en) | 2016-07-28 |
| EP3080293A2 (en) | 2016-10-19 |
| CN105940117A (zh) | 2016-09-14 |
| WO2015087088A3 (en) | 2015-09-17 |
| AU2014363173A1 (en) | 2016-07-07 |
| IL246067A0 (en) | 2016-07-31 |
| KR20160098351A (ko) | 2016-08-18 |
| CA2932553A1 (en) | 2015-06-18 |
| WO2015087088A2 (en) | 2015-06-18 |
| JP2017507320A (ja) | 2017-03-16 |
| GB201322034D0 (en) | 2014-01-29 |
| US20160312294A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016013182A2 (pt) | classificação de câncer de próstata | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| Zhang et al. | Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population. | |
| EA201390762A1 (ru) | Новые биомаркеры для предсказания исхода противораковой иммунотерапии | |
| Zhang et al. | Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| ZA201901962B (en) | Assay for distinguishing between sepsis and systemic inflammatory response syndrome | |
| MX376377B (es) | Configuracion de modo arquitectonico en un sistema de computo. | |
| Ballian et al. | A simplified prognostic system for resected pancreatic neuroendocrine neoplasms | |
| MX2013005067A (es) | Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato. | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| NZ629074A (en) | Biomarkers for gastric cancer and uses thereof | |
| BR112017016808A2 (pt) | biomarcadores para câncer pancreático | |
| EA201790549A1 (ru) | Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método | |
| EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
| Rodic et al. | Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review | |
| HK1222888A1 (zh) | 预测在淋巴结阳性早期乳癌复发风险的方法 | |
| Matuszewska et al. | Immunological markers of rheumatoid arthritis | |
| BR112016029562A2 (pt) | métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica | |
| Dong et al. | Clinical significance of microRNA-24 expression in esophageal squamous cell carcinoma. | |
| Tan et al. | Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma | |
| MX2015013993A (es) | Procedimientos y series para su uso en los mismos. | |
| BR112018013381A2 (pt) | anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo | |
| ES2721477T3 (es) | Materiales y métodos para evaluar la progresión del cáncer de próstata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |